Verve Therapeutics receives FDA Fast Track designation for VERVE-102

Verve Therapeutics (VERV) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol, LDL-C. VERVE-102 is the company’s novel, in vivo, investigational base editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 is currently being tested in the Phase 1b Heart-2 clinical trial, which is designed to evaluate the safety and tolerability of VERVE-102 administration in adult patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease who require additional lowering of LDL-C.